HR Execs on the Move

Imvax

www.imvax.com

 
The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.imvax.com
  • 601 Walnut Street Suite 440 West
    Philadelphia, PA USA 19106
  • Phone: 267.900.4110

Executives

Name Title Contact Details
Arthur Howe
 Co-founder and Chief Financial Officer Profile
Josh Muntner
 Chief Financial Officer Profile
John Furey
 Chief Executive Officer Profile

Similar Companies

Scrippshealth

Scrippshealth is a Lajolla, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ABS Lifesciences

ABS Lifesciences is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Perseus

Perseus is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tonix Pharmaceuticals

Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.

Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.